Preoperative 18F-FDG SUVmax >6.3 or Size >2.3 cm of primary lesions predict lymph nodes metastasis with higher negative predictive value in peripheral cT1 non-small-cell lung cancer
- PMID: 34284441
- DOI: 10.1097/MNM.0000000000001462
Preoperative 18F-FDG SUVmax >6.3 or Size >2.3 cm of primary lesions predict lymph nodes metastasis with higher negative predictive value in peripheral cT1 non-small-cell lung cancer
Abstract
Background: Sublobar resection is suitable for peripheral cT1N0M0 non-small-cell lung cancer (NSCLC). The traditional PET-CT criterion (lymph node size ≥1.0 cm or SUVmax ≥2.5) for predicting lymph nodes metastasis (LNM) has unsatisfactory performance.
Objective: We explore the clinical role of preoperative SUVmax and the size of the primary lesions for predicting peripheral cT1 NSCLC LNM.
Methods: We retrospectively analyzed 174 peripheral cT1 NSCLC patients underwent preoperative 18F-FDG PET-CT and divided into the LNM and non-LNM group by pathology. We compared the differences of primary lesions' baseline characteristics between the two groups. The risk factors of LNM were determined by univariate and multivariate analysis, and we assessed the diagnostic efficacy with the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value and negative predictive value (NPV).
Results: Of the enrolled cases, the incidence of LNM was 24.7%. The preoperative SUVmax >6.3 or size >2.3 cm of the primary lesions were independent risk factors of peripheral cT1 NSCLC LNM (ORs, 95% CIs were 6.18 (2.40-15.92) and 3.03 (1.35-6.81). The sensitivity, NPV of SUVmax >6.3 or size >2.3 cm of the primary lesions were higher than the traditional PET-CT criterion for predicting LNM (100.0 vs. 86.0%, 100.0 vs. 89.7%). A Hosmer-Lemeshow test showed a goodness-of-fit (P = 0.479).
Conclusions: The excellent sensitivity and NPV of preoperative of the SUVmax >6.3 or size >2.3 cm of the primary lesions based on 18F-FDG PET-CT might identify the patients at low-risk LNM in peripheral cT1 NSCLC.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
The value of dual time-point fluorine-18 fluorodeoxyglucose PET/computed tomography imaging in predicting lymph node metastasis in non-small cell lung cancer patients.Nucl Med Commun. 2024 Sep 1;45(9):812-817. doi: 10.1097/MNM.0000000000001866. Epub 2024 May 27. Nucl Med Commun. 2024. PMID: 38803240
-
Tumor-to-liver standard uptake ratio using fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography effectively predict occult lymph node metastasis of non-small cell lung cancer patients.Nucl Med Commun. 2020 May;41(5):459-468. doi: 10.1097/MNM.0000000000001173. Nucl Med Commun. 2020. PMID: 32187163
-
The value on SUV-derived parameters assessed on 18F-FDG PET/CT for predicting mediastinal lymph node metastasis in non-small cell lung cancer.BMC Med Imaging. 2023 Apr 5;23(1):49. doi: 10.1186/s12880-023-01004-7. BMC Med Imaging. 2023. PMID: 37020286 Free PMC article.
-
An Investigation of the Relationship Between 18F-FDG PET/CT Parameters of Primary Tumors and Lymph Node Metastasis in Resectable Non-small Cell Lung Cancer.Curr Radiopharm. 2024;17(1):111-116. doi: 10.2174/1874471016666230829100703. Curr Radiopharm. 2024. PMID: 37644744
-
Predictive Value of 18F-Fluorodeoxyglucose Positron Emission Tomography or Positron Emission Tomography/Computed Tomography for Assessment of Occult Lymph Node Metastasis in Non-Small Cell Lung Cancer.Oncology. 2021;99(2):96-104. doi: 10.1159/000509988. Epub 2020 Sep 25. Oncology. 2021. PMID: 32980838
References
-
- Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3 rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143:e278S–e313S.
-
- Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3 rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143:e211S–e250S.
-
- Yang W, Fu Z, Yu J, Yuan S, Zhang B, Li D, et al. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer. 2008; 61:35–43.
-
- Nambu A, Kato S, Motosugi U, Araki T, Okuwaki H, Nishikawa K, et al. Thin-section CT of the mediastinum in preoperative N-staging of non-small cell lung cancer: comparison with FDG PET. Eur J Radiol. 2010; 73:510–517.
-
- Schmidt-Hansen M, Baldwin DR, Zamora J. FDG-PET/CT imaging for mediastinal staging in patients with potentially resectable non-small cell lung cancer. JAMA. 2015; 313:1465–1466.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical